Archives

Orexigen CEO Michael Narachi elected to PhRMA board of directors

Monday, April 22, 2013 08:00 AM

Michael Narachi, president and CEO of Orexigen Therapeutics, a biopharmaceutical company focused on the treatment of obesity, has been named to the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Narachi will serve as a director for a term of two years.

More... »

Rhythm initiates phase II trial of RM-131 for chronic constipation

Friday, April 19, 2013 08:00 AM

Rhythm, a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases, initiated an additional phase II trial of RM-131, the company's novel ghrelin agonist, for the treatment of chronic constipation. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal motility.

More... »

Icon, UCD Smurfit School launch the Icon Business Academy

Thursday, April 18, 2013 11:18 AM

Icon,a global provider of outsourced development services, has launched the Icon Business Academy in conjunction with University College Dublin (UCD).

More... »

Elorac receives FDA Fast Track designation for naloxone for pruritus

Wednesday, April 17, 2013 12:43 PM

Elorac, a specialty pharmaceutical company focused on the treatment of dermatological disorders, has been granted Fast Track designation by the FDA for its naloxone topical lotion for the relief of pruritus in patients with cutaneous T-cell lymphoma (CTCL). There are currently no approved therapeutic treatment options available to patients and their physicians for pruritus in CTCL.

More... »

Shasun, Debiopharm Group ink licensing agreement for Huperzine-A

Wednesday, April 17, 2013 10:46 AM

Shasun Pharmaceuticals, a global pharmaceutical contracting organization, and Debiopharm Group, a Swiss-based global biopharmaceutical group focused on unmet medical needs, entered into a licensing agreement for the manufacturing and commercialization of Huperzine-A.

More... »

Auris Medical secures $50M Series C financing for inner ear

Wednesday, April 17, 2013 10:15 AM

Auris Medical, a Swiss biotechnology company focused on novel therapeutics for the treatment of inner ear disorders, has completed a $50 million Series C financing. Two leading venture capital firms, Sofinnova Ventures  of Menlo Park, Calif., and Sofinnova Partners of Paris, participated in the financing.

More... »

Santaris Pharma, BMS form discovery alliance for RNA-targeted medicines

Wednesday, April 17, 2013 09:44 AM

Santaris Pharma, a privately held biopharmaceutical company focused on disease-related mRNAs and microRNAs, has formed a worldwide strategic alliance with Bristol-Myers Squibb to discover and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform.

More... »

Cytovance Biologics to expand microbial manufacturing

Tuesday, April 16, 2013 03:17 PM

Cytovance Biologics, a full-service contract manufacturer of mammalian and microbial biologics, plans to expand its microbial manufacturing capabilities. In addition to its current 100L Fermenter, Cytovance recently acquired a second 100L and a 1000L Fermenter.

More... »

Sony, Olympus launch medical device joint venture

Tuesday, April 16, 2013 02:49 PM

Sony and Olympus have launched Sony Olympus Medical Solutions, a medical business venture that aims to align Sony's cutting-edge electronics technologies in areas such as digital imaging with Olympus' manufacturing and R&D expertise in the area of medical products including lenses and optical technologies in order to bring high-quality medical care to as many people as possible, and contribute to medical advancement worldwide.

More... »

Merck opens new manufacturing facility in Hangzhou, China

Tuesday, April 16, 2013 02:05 PM

Global healthcare company Merck has opened its new pharmaceutical manufacturing facility in Hangzhou, China. The facility, located in the Hangzhou Economic and Technology Area (HEDA), will package Merck medicines for China and the Asia Pacific region and will become a critical part of Merck's global supply chain. 

More... »